9PYT | pdb_00009pyt

NMR RDC refinement of the catalytic domain of the SARS-CoV-2 monomeric Main Protease (MPROH41Q,10-306)

SOLUTION NMR

NMR Experiment
Experiment	Type	Sample Contents	Solvent	Ionic Strength	pH	Pressure	Temperature (K)	Spectrometer
1	2D 1H-15N TROSY-HSQC	20 mM sodium chloride, 0.02 % sodium azide, 25 mM HEPES, 1 mM TCEP, 500 uM [U-13C; U-15N; U-2H] MPro(10,306,H41Q)	97% H2O / 3% D2O	20 mM	6.9	1 bar	288	Bruker AVANCE NEO 800
2	3D HNCA	20 mM sodium chloride, 0.02 % sodium azide, 25 mM HEPES, 1 mM TCEP, 500 uM [U-13C; U-15N; U-2H] MPro(10,306,H41Q)	97% H2O / 3% D2O	20 mM	6.9	1 bar	288	Bruker AVANCE NEO 800
3	3D HNCO	20 mM sodium chloride, 0.02 % sodium azide, 25 mM HEPES, 1 mM TCEP, 500 uM [U-13C; U-15N; U-2H] MPro(10,306,H41Q)	97% H2O / 3% D2O	20 mM	6.9	1 bar	288	Bruker AVANCE NEO 800
4	3D HNCB	20 mM sodium chloride, 0.02 % sodium azide, 25 mM HEPES, 1 mM TCEP, 500 uM [U-13C; U-15N; U-2H] MPro(10,306,H41Q)	97% H2O / 3% D2O	20 mM	6.9	1 bar	288	Bruker AVANCE NEO 800
5	3D HN(COCA)CB	20 mM sodium chloride, 0.02 % sodium azide, 25 mM HEPES, 1 mM TCEP, 500 uM [U-13C; U-15N; U-2H] MPro(10,306,H41Q)	97% H2O / 3% D2O	20 mM	6.9	1 bar	288	Bruker AVANCE NEO 800
6	4D 1H-15N TROSY-NOESY-TROSY	20 mM sodium chloride, 0.02 % sodium azide, 25 mM HEPES, 1 mM TCEP, 500 uM [U-13C; U-15N; U-2H] MPro(10,306,H41Q)	97% H2O / 3% D2O	20 mM	6.9	1 bar	288	Bruker AVANCE NEO 800
7	2D 1H-15N ARTSY	20 mM sodium chloride, 0.02 % sodium azide, 25 mM HEPES, 1 mM TCEP, 430 uM [U-13C; U-15N; U-2H] MPro(10,306,H41Q), 13 mg/mL Pf1 phage	97% H2O / 3% D2O	20 mM	6.9	1 bar	298	Bruker AVANCE NEO 800
8	2D 15-15N QJNC' TROSY	20 mM sodium chloride, 0.02 % sodium azide, 25 mM HEPES, 1 mM TCEP, 430 uM [U-13C; U-15N; U-2H] MPro(10,306,H41Q), 13 mg/mL Pf1 phage	97% H2O / 3% D2O	20 mM	6.9	1 bar	298	Bruker AVANCE NEO 800
9	3D TATER-HNCO	20 mM sodium chloride, 0.02 % sodium azide, 25 mM HEPES, 1 mM TCEP, 430 uM [U-13C; U-15N; U-2H] MPro(10,306,H41Q), 13 mg/mL Pf1 phage	97% H2O / 3% D2O	20 mM	6.9	1 bar	298	Bruker AVANCE NEO 600
10	3D QJC'CA HNCO	20 mM sodium chloride, 0.02 % sodium azide, 25 mM HEPES, 1 mM TCEP, 430 uM [U-13C; U-15N; U-2H] MPro(10,306,H41Q), 13 mg/mL Pf1 phage	97% H2O / 3% D2O	20 mM	6.9	1 bar	298	Bruker AVANCE NEO 600
11	3D ARTSY-HNCO	20 mM sodium chloride, 0.02 % sodium azide, 25 mM HEPES, 1 mM TCEP, 430 uM [U-13C; U-15N; U-2H] MPro(10,306,H41Q), 13 mg/mL Pf1 phage	97% H2O / 3% D2O	20 mM	6.9	1 bar	298	Bruker AVANCE NEO 600

NMR Spectrometer Information
Spectrometer	Manufacturer	Model	Field Strength
1	Bruker	AVANCE NEO	800
2	Bruker	AVANCE NEO	600

NMR Refinement
Method	Details	Software
simulated annealing		X-PLOR NIH

NMR Ensemble Information
Conformer Selection Criteria	all calculated structures submitted
Conformers Calculated Total Number	10
Conformers Submitted Total Number	10
Representative Model	1 (lowest energy)

Computation: NMR Software
#	Classification	Version	Software Name	Author
1	refinement	X-PLOR NIH		Schwieters, Kuszewski, Tjandra and Clore
2	processing	NMRPipe		Delaglio, Grzesiek, Vuister, Zhu, Pfeifer and Bax
3	chemical shift assignment	CcpNmr Analysis		CCPN

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM157729.